Evidence map›Paper›PMID 26772725›Full record

ArticleNew biotechnology2016

A comparison of phosphospecific affinity reagents reveals the utility of recombinant Forkhead-associated domains in recognizing phosphothreonine-containing peptides.

Leon A Venegas, Kritika Pershad, Oluwadamilola Bankole, Noman Shah, Brian K Kay

Open access · greenAbstract read
In one paragraph

Article in New biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. A Recombinant Affinity Reagent Specific for a Phosphoepitope of Akt1.International journal of molecular sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Leon A VenegasDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.
Kritika PershadDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.
Oluwadamilola BankoleDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.
Noman ShahDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.
Brian K KayDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA. Electronic address: bkay@uic.edu.
University of Illinois Chicago · US

Funding

Technology Development for Recombinant Affinity ReagentsU54DK093444 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KAY, BRIAN KENNETH · 2011 to 2013
$3.6M
NIDDK NIH HHS U54 DK093444
6 · The paper itself

Abstract

Phosphorylation is an important post-translational event that has a wide array of functional consequences. With advances in the ability of various technologies in revealing and mapping new phosphosites in proteins, it is equally important to develop affinity reagents that can monitor such post-translational modifications in eukaryotic cells. While monoclonal and polyclonal antibodies have been shown to be useful in assessing the phosphoproteome, we have expanded our efforts to exploit the Forkhead-associated 1 (FHA1) domain as scaffold for generating recombinant affinity reagents that recognize phosphothreonine-containing peptides. A phage display library of FHA1 variants was screened by affinity selection with 15 phosphothreonine-containing peptides corresponding to various human transcription factors and kinases, including human Myc, calmodulin-dependent protein kinase II (CaMKII), and extracellular-signal regulated kinases 1 and 2 (ERK1/2). The library yielded binding variants against 10 targets (66% success rate); success was largely determined by what residue occurred at the +3 position (C-terminal) to the pThr moiety (i.e., pT+3). The FHA domains binding Myc, CaMKII, and ERK1/2 were characterized and compared against commercially available antibodies. All FHA domains were shown to be phosphorylation-dependent and phosphothreonine-specific in their binding, unlike several commercial monoclonal and polyclonal antibodies. Both the pThr and the residue at the pT+3 position were major factors in defining the specificity of the FHA domains.

Indexed as

Affinity LabelsAmino Acid SequenceAntibodiesBiotechnologyForkhead Transcription FactorsHumansModels, MolecularPeptide LibraryPeptidesPhosphothreonineProtein DomainsProtein Interaction Domains and MotifsRecombinant ProteinsAffinity LabelsAntibodiesForkhead Transcription FactorsPeptide LibraryPeptidesPhosphothreonineRecombinant Proteins

Identifiers

PMID26772725
PMCPMC4912404
OpenAlexW2232391206

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.